By Julie Steenhuysen and Ben Hirschler CHICAGO/LONDON (Reuters) - In 2006 when doctors started testing a melanoma treatment made by Roche Holding AG on patients, they were used to facing slim odds - about one in eight - that the tumors would shrink on chemotherapy. This time, they couldn't believe their eyes. With Zelboraf, a drug that targets specific mutations in cancer cells, eight out of 10 patients in an early-stage trial experienced significant tumor shrinkage. Roche clearly had a remarkable drug, though it only worked for people with a specific genetic makeup. ...
via Health News Headlines - Yahoo! News http://news.yahoo.com/insight-cancer-drugs-skip-randomized-trials-091247195--finance.html
No comments:
Post a Comment